Last update Jan. 11, 2020

Goserelin

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a GNRH analogue that works like an inhibitor of Hypophysis Gonadotropin (LH & FSH) secretion. A continue use produces a decrease of Estradiol level to those seen during the post-menopause period.

At latest update, no relevant published data concerning excretion into breast milk were found.

Its high molecular weight makes excretion into breast milk be unlikely. Also, a low oral bioavailability renders the absorption of this agent into the infant's plasma be nil or minimal.


See below the information of these related products:

  • Assisted Reproductive Techniques (ART) (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Gonadorelin (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

We do not have alternatives for Goserelin.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Goserelin is also known as


Goserelin in other languages or writings:

Group

Goserelin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Goserelin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.269 daltons
Protein Binding 27 %
VD 0.3 - 0.6 l/Kg
pKa 9.27 -
T½ 2.3 hours

References

  1. PDR.NET Goserelin Drug Summary 2014 Full text (link to original source) Full text (in our servers)
  2. AEPMS Goserelina Ficha técnica 2014 Full text (link to original source) Full text (in our servers)
  3. Cavagna M, Mantese JC, Freitas Gda C, Dzik A, Soares JB, Hameiry Y, Izzo VM, Pinotti JA. Pattern of prolactin secretion after administration of gonadotropin-releasing hormone agonist at the preovulatory phase of intrauterine insemination cycles. Sao Paulo Med J. 2005 Nov 3;123(6):295-7. Epub 2006 Jan 20. Abstract
  4. Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000 Abstract
  5. Perry CM, Brogden RN. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs. 1996 Abstract
  6. Chantilis SJ, Barnett-Hamm C, Byrd WE, Carr BR. The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women. Fertil Steril. 1995 Oct;64(4):698-702. Abstract
  7. Kamel MA, Zabel G, Bernart W, Neulen J, Breckwoldt M. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme. Hum Reprod. 1994 Oct;9(10):1803-6. Abstract
  8. Van Leusden HA. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol. 1994 Sep;8(3):215-22. Review. Abstract
  9. Fraser HM. GnRH analogues for contraception. Br Med Bull. 1993 Jan;49(1):62-72. Review. Abstract
  10. Meldrum DR, Cedars MI, Hamilton F, Huynh D, Wisot A, Marr B. Leuprolide acetate elevates prolactin during ovarian stimulation with gonadotropins. J Assist Reprod Genet. 1992 Jun;9(3):251-3. Abstract
  11. Fraser HM, Dewart PJ, Smith SK, Cowen GM, Sandow J, McNeilly AS. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women. J Clin Endocrinol Metab. 1989 Nov;69(5):996-1002. Abstract
  12. Dewart PJ, McNeilly AS, Smith SK, Sandow J, Hillier SG, Fraser HM. LRH agonist buserelin as a post-partum contraceptive: lack of biological activity of buserelin in breast milk. Acta Endocrinol (Copenh). 1987 Feb;114(2):185-92. Abstract

Total visits

3,216

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM